Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636852 · ClinicalTrials.gov registry record · Phase 2
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
A Phase 2 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05636852 is a Phase 2 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 15 participants.
The verdict
NCT05636852, a Phase 2 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
Interventions
- DRUG Altropane (123I) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2024-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05636852
The ClinicalTrials.gov registry entry for NCT05636852 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Altropane (123I) Injection is the first listed.
NCT05636852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05636852 about?
NCT05636852 is a clinical study titled "Altropane Dose for Imaging Patients With Suspected Parkinson's Disease". Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
What is the current status of trial NCT05636852?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-04-24. Estimated completion is 2024-06-08.
What interventions are being tested in trial NCT05636852?
The interventions under investigation include: Altropane (123I) Injection (DRUG).
Who is sponsoring clinical trial NCT05636852?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.